ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-Guided Analysis.
Víctor A ArrietaJohnny DuerinckKirsten Bell BurdettKarl John HabashyWietse GeensAndrew GouldJulia Katharina SchwarzeCrismita DmelloKwang-Soo KimRuth SagantyLi ChenAlberto MosconaMatthew McCordCatalina Lee-ChangCraig M HorbinskiM-Marsel MesulamRoger StuppBart NeynsAdam M SonabendPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
This study strengthens the role of p-ERK as a predictive biomarker for OS in glioblastoma patients on immune checkpoint blockade. Future research should focus on further validation in prospective trials and the standardization of preanalytical variables influencing p-ERK quantification.